<DOC>
	<DOCNO>NCT01108042</DOCNO>
	<brief_summary>A combination therapy Docetaxel , Cisplatin und 5-Fluorouracil ( = TPF ) use patient resectable oropharyngeal cavity mouth cancer . To improve compatibility TPF-induction without decrease efficacy dose give day 1 8 instead apply whole dose day 1 every 3 week . In phase I-part trial optimal therapeutic dose Docetaxel Cisplatin define . In phase II-part progression-free survival 2 year assess patient treat optimal therapeutic dose .</brief_summary>
	<brief_title>TPF-Induction Chemotherapy Oropharyngeal Cavity Mouth Cancer</brief_title>
	<detailed_description>Local advance Oropharyngeal cavity mouth Cancer often treat combination surgery and/or radiation /or chemotherapy . Despite therapy improvement little advance progression-free survival overall survival . Therefore new therapy concept need . The advantage induction chemotherapy possibility tumor response assessment chemotherapy may present selection criterion organ preservation . In order minimize time chemotherapy surgery important early answer tumor response . In study response assess first cycle chemotherapy . Patients show tumor response operate . The patient receive cycle chemotherapy . Toxicity induction chemotherapy moderate surgery delayed . To improve tolerance induction therapy medication dose n't give day 1 every 3 week , disperse day 1 day 8 , q3weeks .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histological proven , resectable squamous epithelial carcinoma oropharynx cavity mouth 2 . R0resection possible 3 . All T N2 M0 / T N3 M0 / T3 T4a also N01 M0 4 . Leucocytes &gt; 4000/mm³ bzw . neutrophil &gt; 2000/mm³ , thrombocytes &gt; 100000/mm³ 5. adequate kidney function , define serum creatinine und urea normal range , Creatinine clearance &gt; 60 ml/min 6. adequate liver function glutamate oxaloacetate transaminase ( SGOT ) , glutamate pyruvate transaminase ( SGPT ) bilirubin normal range 7. electrolyte normal range 8. risk anesthesia complication normal minor increase 9 . Eastern Cooperative Oncology Group ( ECOG ) 02 / Karnofsky &gt; = 60 % 10 . Age 18 80 year 11. sign write informed consent 12. effective contraception male female subject risk conception exist 13 . T1 N0 M0 / T1 N1 M0 / T2 N0 M0 / T2 N1 M0 14 . Resection without curative intention : primary tumor treatable resection method 15 . Infiltration low jaw 16 . M1 status 17 . Tumor measurable Innovation Center Computer Assisted Surgery ( ICCAS ) methods 18 . No prior chemotherapy radiation ( primary surgery allow ) 19 . Metachronous oder synchronous malignoma ( Exception : basal cell carcinoma ) 20 . Life expectance &lt; 3 month 21 . ECOG &gt; 2 ; Karnofsky &lt; 60 % 22. acute infection fever 23. known HIVinfection immune suppression 24. severe cardio pulmonary concomitant diseases 25. chronic disease continuous therapy ( uncontrolled diabetes , rheumatoid arthritis ) especially continuous therapy steroid 26. concomitant disease , investigator 's opinion , would exclude patient study 27 . Contraindications permit therapy Docetaxel , Cisplatin , 5FU radiation therapy 28. miss patient 's compliance 29. regular Followup visit possible 30 . Pregnancy lactation period 31. legal incapacity limited legal capacity 32 . Participation another clinical trial administration approve substance within 30 day registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>